Skip to search formSkip to main contentSkip to account menu

CYT006-AngQb

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2012
Review
2012
Therapeutic Potential of Vaccines in the Management of Hypertension
Therapeutic vaccination is an exciting new development in hypertension, but proof-of-concept in the clinic is not yet clearly… 
2009
2009
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study
2008
2008
Rituximab is effective against lupus nephritis in children
and efficacy of CYT006-AngQb—a vaccine comprising angiotensin II conjugated to recombi nant virus-like particles—in 72 patients… 
2008
2008
Low blood pressure does protect against stroke in CKD
and efficacy of CYT006-AngQb—a vaccine comprising angiotensin II conjugated to recombi nant virus-like particles—in 72 patients… 
2008
2008
Therapeutic Vaccines in Hypertension 2559 Table I . Change from baseline in ambulatory blood pressure for treatment groups in a phase IIa trial of the angiotensin vaccine AngQb
Therapeutic vaccination is an exciting new development in hypertension, but Abstract proof-of-concept in the clinic is not yet… 
2007
2007
Abstract 2519: CYT006-AngQb, a Vaccine Against Hypertension Targeting Angiotensin II, Reduces Early-Morning and Day-Time Blood Pressure
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)